AUTL Valuation

Autolus Therapeutics PLC

Add to Watchlist

Advanced Chart

1.500

-0.07(-4.459%)1D

Overview
Forecast
Valuation
Earnings

AUTL Relative Valuation

AUTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AUTL is overvalued; if below, it's undervalued.

Historical Valuation

Autolus Therapeutics PLC (AUTL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.86 is considered Undervalued compared with the five-year average of -3.21. The fair price of Autolus Therapeutics PLC (AUTL) is between 1.58 to 8.72 according to relative valuation methord. Compared to the current price of 1.52 USD , Autolus Therapeutics PLC is Undervalued By 3.71%.

Relative Value

Fair Zone

1.58-8.72

Current Price：1.52

3.71%

Undervalued

-1.87

Trailing

Forward

-1.29

EV/EBITDA

Autolus Therapeutics PLC. (AUTL) has a current EV/EBITDA of -1.29. The 5-year average EV/EBITDA is -2.21. The thresholds are as follows: Strongly Undervalued below -5.63, Undervalued between -5.63 and -3.92, Fairly Valued between -0.50 and -3.92, Overvalued between -0.50 and 1.21, and Strongly Overvalued above 1.21. The current Forward EV/EBITDA of -1.29 falls within the Historic Trend Line -Fairly Valued range.

-1.31

EV/EBIT

Autolus Therapeutics PLC. (AUTL) has a current EV/EBIT of -1.31. The 5-year average EV/EBIT is -1.89. The thresholds are as follows: Strongly Undervalued below -5.03, Undervalued between -5.03 and -3.46, Fairly Valued between -0.32 and -3.46, Overvalued between -0.32 and 1.25, and Strongly Overvalued above 1.25. The current Forward EV/EBIT of -1.31 falls within the Historic Trend Line -Fairly Valued range.

3.86

Autolus Therapeutics PLC. (AUTL) has a current PS of 3.86. The 5-year average PS is 160.93. The thresholds are as follows: Strongly Undervalued below -207.90, Undervalued between -207.90 and -23.49, Fairly Valued between 345.34 and -23.49, Overvalued between 345.34 and 529.75, and Strongly Overvalued above 529.75. The current Forward PS of 3.86 falls within the Historic Trend Line -Fairly Valued range.

-2.41

P/OCF

Autolus Therapeutics PLC. (AUTL) has a current P/OCF of -2.41. The 5-year average P/OCF is -3.98. The thresholds are as follows: Strongly Undervalued below -9.20, Undervalued between -9.20 and -6.59, Fairly Valued between -1.38 and -6.59, Overvalued between -1.38 and 1.23, and Strongly Overvalued above 1.23. The current Forward P/OCF of -2.41 falls within the Historic Trend Line -Fairly Valued range.

-1.99

P/FCF

Autolus Therapeutics PLC. (AUTL) has a current P/FCF of -1.99. The 5-year average P/FCF is -3.44. The thresholds are as follows: Strongly Undervalued below -7.73, Undervalued between -7.73 and -5.59, Fairly Valued between -1.29 and -5.59, Overvalued between -1.29 and 0.85, and Strongly Overvalued above 0.85. The current Forward P/FCF of -1.99 falls within the Historic Trend Line -Fairly Valued range.

Autolus Therapeutics PLC (AUTL) has a current Price-to-Book (P/B) ratio of 1.21. Compared to its 3-year average P/B ratio of 2.43 , the current P/B ratio is approximately -50.39% higher. Relative to its 5-year average P/B ratio of 2.11, the current P/B ratio is about -42.94% higher. Autolus Therapeutics PLC (AUTL) has a Forward Free Cash Flow (FCF) yield of approximately -71.62%. Compared to its 3-year average FCF yield of -32.00%, the current FCF yield is approximately 123.78% lower. Relative to its 5-year average FCF yield of -33.00% , the current FCF yield is about 117.01% lower.

1.21

P/B

Median3y

2.43

Median5y

2.11

-71.62

FCF Yield

Median3y

-32.00

Median5y

-33.00

Competitors Valuation Multiple

The average P/S ratio for AUTL's competitors is 12.52, providing a benchmark for relative valuation. Autolus Therapeutics PLC Corp (AUTL) exhibits a P/S ratio of 3.86, which is -69.16% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AUTL.O

Autolus Therapeutics PLC

Solid Biosciences Inc

Loss

426.72M

PRTA.O

Prothena Corporation PLC

Iteos Therapeutics Inc

Performance Decomposition

Market capitalization of AUTL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of AUTL in the past 1 year is driven by Unknown.